Johnson & Johnson is now planning to reestablish its footprint in the fast expanding market of HCV drugs. Its triple combo HCV treatment has produced positive results as per an interim data analysis published yesterday; this cocktail holds the capability to offer a breakthrough cure by cutting down the treatment duration of the debilitating liver disease even further. Other big players in the HCV market like Merck,AbbVie and especially Gilead should be cautious of J&J’s progress in the field.
